Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Aug;122(8):2756-62.
doi: 10.1172/JCI60323. Epub 2012 Aug 1.

Pulmonary fibrosis: patterns and perpetrators

Paul W Noble  1 , Christina E Barkauskas, Dianhua Jiang
Affiliations
Review

Pulmonary fibrosis: patterns and perpetrators

Paul W Noble et al. J Clin Invest. 2012 Aug.

Abstract

Pulmonary fibrosis occurs in a variety of clinical settings, constitutes a major cause of morbidity and mortality, and represents an enormous unmet medical need. However, the disease is heterogeneous, and the failure to accurately discern between forms of fibrosing lung diseases leads to inaccurate treatments. Pulmonary fibrosis occurring in the context of connective tissue diseases is often characterized by a distinct pattern of tissue pathology and may be amenable to immunosuppressive therapies. In contrast, idiopathic pulmonary fibrosis (IPF) is a progressive and lethal form of fibrosing lung disease that is recalcitrant to therapies that target the immune system. Although animal models of fibrosis imperfectly recapitulate IPF, they have yielded numerous targets for therapeutic intervention. Understanding the heterogeneity of these diseases and elucidating the final common pathways of fibrogenesis are critical for the development of efficacious therapies for severe fibrosing lung diseases.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Fibrotic NSIP.
(A) Chest CAT scan from a 60-year-old woman with 6 months of cough, exertional breathlessness, and fatigue. (B) Surgical lung biopsy shows a homogenous pattern of fibrosis and chronic inflammation with a paucity of normal lung. Magnification, ×40. (C) Chest CAT after treatment with a combination of prednisone and mycophenolate mofetil.
Figure 2
Figure 2. Classic usual interstitial pneumonia.
(A) Chest CAT scan demonstrating the cardinal radiographic features of IPF: subpleural honeycombing, traction bronchiectasis, and thickened interlobular septae. (B) Lung biopsy demonstrating the cardinal pathologic manifestations of UIP: a variegated pattern of chronic interstitial fibrosis, subpleural accentuation, and fibroblastic foci. (C) Lung biopsy demonstrating a fibroblast focus without accompanying inflammation. (B and C) Magnification, ×40.
Figure 3
Figure 3. A UIP pattern in the absence of IPF.
(A) Chest CAT scan from a 68-year-old man who presented with cough and exertional breathlessness that demonstrates subpleural reticular opacities but without definitive honeycombing. (B) Surgical lung biopsy revealed a variegated pattern of chronic interstitial fibrosis without microscopic honeycombing but with fibroblastic foci and areas of mononuclear inflammation. Magnification in B, ×40; C is a higher-magnification view of boxed area in B.
Figure 4
Figure 4. Model of the relationship between ER stress and lung fibrosis.
Genetic predisposition such as mutations in surfactant protein genes renders AEC2s vulnerable to environmental insults such as viral infections and cigarette smoking. These insults may result in the accumulation of misfolded proteins in the ER. Persistent injury may lead to ER stress and eventually to epithelial cell apoptosis. However, ER stress leading directly to pulmonary fibrosis in the absence of injury remains to be demonstrated.
Figure 5
Figure 5. Proposed mechanisms of severe lung fibrosis.
Injured AEC2s attempting to repair damage release growth factors, cytokines, coagulants, and other substances. These factors promote mesenchymal expansion and activation, leading to the accumulation of matrix-producing and invasive fibroblasts/myofibroblasts. Figure adapted with permission from the American Journal of Respiratory Cell and Molecular Biology (2).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Interstitial Lung Disease. Schwarz MI, King TE Jr, eds. 5th ed. Shelton, Connecticut, USA: People’s Medical Publishing House; 2010.
    1. Noble PW, Homer RJ. Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2005;33(2):113–120. doi: 10.1165/rcmb.F301. - DOI - PubMed
    1. Fischer A, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103(11):1719–1724. doi: 10.1016/j.rmed.2009.05.001. - DOI - PMC - PubMed
    1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3:8. doi: 10.1186/1750-1172-3-8. - DOI - PMC - PubMed
    1. Hunninghake GW, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164(2):193–196. - PubMed

Publication types

MeSH terms

-